| Drug Name |
Lurasidone hydrochloride |
| Drug ID |
BADD_D01331 |
| Description |
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. |
| Indications and Usage |
Treatment of schizophrenia. |
| Marketing Status |
Prescription |
| ATC Code |
N05AE05 |
| DrugBank ID |
DB08815
|
| KEGG ID |
D04820
|
| MeSH ID |
D000069056
|
| PubChem ID |
11237860
|
| TTD Drug ID |
D01QGX
|
| NDC Product Code |
13668-466; 13668-467; 51148-001; 65015-843; 62756-947; 46708-497; 63402-312; 58032-2024; 51148-002; 50370-0033; 46708-496; 46708-495; 13668-465; 38217-0014; 66039-897; 38217-0011; 46708-498; 63402-304; 63402-308; 38217-0013; 65085-0053; 70518-3010; 63402-306; 65372-1192; 46016-3672; 46708-494; 17373-1185; 38217-0015; 63402-302; 65977-0103; 51148-004; 51148-003; 46016-3671; 38217-0012; 66583-0516; 38217-0010; 69011-0004; 53747-058; 70518-1936; 42765-009; 76072-1007; 70518-1812; 13668-464 |
| Synonyms |
Lurasidone Hydrochloride | Hydrochloride, Lurasidone | Lurasidone HCl | HCl, Lurasidone | SM 13496 | 13496, SM | SM13496 | SM-13,496 | SM 13,496 | SM13,496 | SM-13496 | Lurasidone | N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide | Latuda |
